Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title Date of Registration State
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment. 2010-12-29 Registered
14F7 MAb marked with Tc99 Phase II in breast tumors. 2010-12-29 Registered
Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients 2010-12-28 Registered
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients 2010-12-28 Registered
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. 2010-12-28 Registered
hR3 MaB and radiotherapy in highly malignant astrocytic tumors, phase III. 2010-12-28 Registered
1E10 anti-idiotype vaccine, metastatic breast cancer, phase II 2010-12-27 Registered
Evaluation of Safety and Efficacy of T1h (anti-CD6) as Monotherapy and in Combination with Methotrexate in Patientes with Rheumatoid Arthritis 2010-12-27 Registered
188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I. 2010-12-27 Registered
Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III. 2010-12-27 Registered
Toxicological evaluation of the humanized Anti-CD6 MAb T1h in Rheumatoid Arthritis Patients 2010-12-24 Registered
Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I. 2010-12-17 Registered
NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II 2010-12-17 Registered
99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II 2010-12-17 Registered
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III. 2010-12-17 Registered
Use of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors. 2010-12-17 Registered
1E10 anti-idiotype vaccine, metastatic colon, phase II. 2010-12-03 Registered
99mTc-marked 14F7 MaB in metastatic breast, phase II 2008-12-27 Registered
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial 17/10/2018 Registered
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors 17/02/2017 Registered